Aflatoxin and liver cancer: microRNAs remain experimental markers

MicroRNAs could help identify some liver cancers associated with aflatoxin B1, a foodborne carcinogen. But a scoping review highlights a major gap: of 104 studies, only one directly linked measured exposure, liver cancer and microRNA analysis in humans. These candidates are therefore not yet validated clinical tests.

Illustration of a liver and microRNAs being studied as markers of cancers associated with aflatoxin B1.
NutritionEditorial illustration, not study data.

Distinguishing the effects of aflatoxin from those of cancer

The central question in this review is specificity: do changes in microRNAs reflect liver cancer associated with aflatoxin B1, or simply mechanisms common to hepatocellular carcinomas? This distinction determines their value as markers of cancer linked to this dietary exposure.

The authors identified studies published between 2016 and 2026 in four bibliographic databases, with an additional search of reference lists. They classified the 104 included studies by evidence type and the strength of the link to aflatoxin. Experimental studies of mechanisms made up the majority.

An encouraging but isolated signal in humans

The only study directly combining all three dimensions in humans included 366 people with hepatocellular carcinoma and 662 controls. Circulating microRNA miR-4651 showed the most convincing clinical signal in this setting, with an area under the curve of 0.85, a sensitivity of 78.1% and a specificity of 92.1% for distinguishing cancers classified as aflatoxin-positive.

These performance figures describe discriminatory ability within that particular study. They demonstrate neither the effectiveness of population screening nor an improvement in care. The review calls for multicentre validation incorporating exposure measurement, harmonised analytical methods and prospective evaluation.

Plausible mechanisms are not enough

The studies reviewed implicate DNA damage, oxidative stress, inflammation and metabolic disturbances, among other mechanisms. However, the mechanisms identified varied across studies, and independent functional confirmation remained limited.

The review also distinguishes between findings that are not interchangeable: liver toxicity, experimental malignant transformation and cancer development in rats. None of these findings is sufficient to validate a human diagnostic test. Machine learning approaches also remain limited by exposures that are often inferred rather than measured and by a lack of external validation.

Limitations to keep in mind

This news article is based solely on the supplied PubMed abstract, without access to the full text. Methodological details, the quality of each study, funding and conflicts of interest could not be verified. Human evidence directly linked to measured exposure remains very scarce.

What we can take away

The main finding is a limitation: microRNAs are research candidates, not yet validated tools for identifying liver cancers associated with aflatoxin.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.